Myriad Genetics Sues Again After Supreme Court Ruling

Myriad Genetics (NASDAQ: MYGN  ) , almost one month after a landmark ruling in the U.S. Supreme Court both undermined and supported the company's claim of patents for the BRCA1 and BRCA2 genes, has filed suit against a company it says has infringed on those patents.

The BRCA genes are used to test for increased risk of breast cancer.

In its ruling of June 13, the Supreme Court unanimously found that Myriad could not hold a patent on naturally occurring human genes but could patent what's known as synthetic DNA, DNA that has been changed in the laboratory to alter its natural state.

Today, Myriad filed a lawsuit in the United States District Court for the District of Utah against diagnostic testing company Ambry Genetics. Myriad alleges that Ambry infringed on Myriad's synthetic DNA and methods of use in regard to the BRCA1 and BRCA2 genes.

Myriad is seeking a preliminary injunction to stop Ambry from selling products that use Myriad's patents. Myriad is also seeking treble damages for any profits lost if found that Ambry willfully infringed on the patents.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2529263, ~/Articles/ArticleHandler.aspx, 4/17/2014 12:04:21 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement